Research Progress on Lympho Proliferative Diseases after Lung Transplantation

Yue Ma, Jun Chen*

Received: August 03, 2018;   Published: August 13, 2018

DOI: 10.26717/BJSTR.2018.07.001568

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

With the development of surgical methods and pharmaceutical preparations, more patients with benign end-stage lung disease can receive treatment of lung transplants. Not only the number of surgeries has increased to 4,000 per year, but also the survival time has been growing longer. Ten years ago, a lot of medical experts thought that post-transplant lymphoproliferative disease was a rare disease, but this disease has received more and more attention because of increasing of surgeries. PTLD is a serious and rare post-transplant complication. Compared with other organ transplants, the incidence of heart, lung, and heart lung transplantation is extremely high. The 5-year survival rate is 29%, and the median survival period is 10month. Risk factors for morbidity are related to the use of immunosuppressive agents, viral infections, type of transplanted organ, gender, age et al. This article will describe the incidence, risk factors, pathogenic mechanism, treatment methods and latest research progress of lymphoproliferative diseases after lung transplantation recently by providing new ideas on hotspots.

Keywords: Lung transplantation; Post transplant Lymphoproliferative Disorders; Immunosuppressants; Viral infection

Abstract | Introduction | Conclusion | References |